Inside Oxford’s Biotech Hub: A Scientific Powerhouse Situated in the U.K.’s Golden Triangle
Oxford has cemented its status as a leading European biotech hub, anchored by the University of Oxford’s deep biomedical expertise and a thriving spin‑out ecosystem. The Oxford Science Park now houses nearly 100 life‑science companies, while the £1.2 bn Oxford North campus adds a million square feet of flexible lab space. Over the past decade, Oxford‑based firms have attracted hundreds of millions of pounds in private and public funding, and the city boasts a record 53 pharmaceutical spin‑outs. This combination of world‑class research, infrastructure, and capital makes Oxford a cornerstone of the UK’s Golden Triangle.
Accelerating Rare Disease Cures with ASOs, Gene Editing, and AI
Professor Matthew Wood, Oxford’s leading neuroscientist, heads the Oxford‑Harrington Rare Disease Centre, a partnership designed to fast‑track therapies for rare neuromuscular and genetic disorders. He outlines a vision to make antisense oligonucleotides (ASOs) and gene‑editing tools more modular, scalable, and...
Innovation in Ophthalmology: How Biotechs Are Reshaping the Treatment of Eye Diseases
Vision loss remains a leading disability, prompting biotech firms to shift from symptom‑management to disease‑modifying therapies. Gene‑replacement approaches using AAV vectors dominate the inherited retinal disease pipeline, highlighted by Luxturna’s success and multiple late‑stage candidates such as Beacon’s laru‑zova and...
Six Biotechs to Know in Barcelona
Barcelona is emerging as a premier European life‑sciences hub, contributing 7.6 % of Catalonia’s GDP and ranking sixth in scientific output. Six local biotech firms—Accure Therapeutics, Oryzon Genomics, SpliceBio, Peptomyc, Ona Therapeutics and Integra Therapeutics—are advancing diverse modalities from small‑molecule neuroprotectors...
Can Treg Cell Therapy Really Target Autoimmunity?
Regulatory T‑cell (Treg) therapies are moving from discovery to clinic, with multiple biotech firms reporting early clinical data. Sonoma Biotherapeutics’ CAR‑Treg candidate SBT‑77‑7101 achieved a 67% reduction in rheumatoid‑arthritis swelling in a Phase 1 trial, while Coya Therapeutics secured IND approval...
Using AI to Crack Undruggable Drug Targets
ProPhet, an Israeli AI‑driven startup founded in late 2024, leverages a novel machine‑learning platform that projects proteins and small molecules into a common interaction space. This approach allows the company to screen billions of compounds against targets previously deemed undruggable,...
Seven Influential Women in Biotech in 2026
The article spotlights seven women reshaping biotech in 2026, from Shehnaaz Suliman’s $29 million‑funded mRNA program at ReCode to Julie Kim’s historic appointment as Takeda’s first female CEO. It details their strategic wins—such as Vertex’s CRISPR therapy approval under Reshma Kewalramani...
Eight Biotech Companies Spearheading the Antibody Drug Conjugate New Wave
A new wave of eight biotech firms is redefining antibody‑drug conjugates (ADCs) by pursuing unconventional targets, advanced linker chemistries, and novel cytotoxic payloads. Companies such as Adcendo, Adcentrx, and Tubulis are advancing phase 1/2 programs that address sarcoma, Nectin‑4, NaPi2b, and...
Astellas’ “Strategic Brands” And “Primary Focuses” After XTANDI
Astellas is reshaping its portfolio as XTANDI nears patent expiry, shifting from a single‑product reliance to a set of “strategic brands.” The company is promoting approved assets such as PADCEV, VYLOY, VEOZAH and IZERVAY to smooth revenue across oncology, menopause...
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
The breast‑cancer pipeline is heating up as several late‑stage candidates demonstrate significant efficacy across sub‑types. Roche’s oral SERD giredestrant cut invasive disease recurrence by 30% in early‑stage ER‑positive patients, while AstraZeneca’s camizestrant combined with a CDK4/6 inhibitor reduced progression risk...
Top Biotech Deals in January 2026
January 2026 saw a slowdown in headline biopharma M&A, yet the deals that closed were strategically sizable. Amgen bought Dark Blue Therapeutics for $840 million, adding an AML protein‑degrader, while GSK acquired RAPT Therapeutics for $2.2 billion to expand its anti‑IgE portfolio....
How Eli Lilly’s Biotech Collaboration Model Is Rewriting Early-Stage Innovation
Eli Lilly’s ExploR&D program redefines pharma‑biotech partnerships by offering early‑stage companies shared‑risk, full‑stack R&D support. The model integrates Lilly’s discovery, chemistry, and clinical teams to accelerate the journey from molecule creation to proof‑of‑concept, especially in a tightening funding environment. It focuses...
The Biggest Biotech Funding Rounds in January 2026
In January 2026 biotech firms secured record capital, with Parabilis Medicines leading private rounds at $305 million and Aktis Oncology topping public offerings at $365.4 million. Private fundraising totaled $2.986 billion across 31 rounds, while public markets raised $1.67 billion from nine offerings. Oncology and...
Nine Biotech Companies that Could Revolutionize Obesity Treatments
A slate of nine biotech firms is accelerating the race to treat obesity, each advancing GLP‑1, GIP or novel oral formulations toward market approval. Early‑stage data from companies such as Zealand Pharma, Viking Therapeutics and Structure Therapeutics report weight‑loss results...
Amarin V. Hikma: Settling the Skinny Label Question
The U.S. Supreme Court has agreed to hear Amarin Pharma’s claim that Hikma Pharmaceuticals’ skinny‑label generic of Vascepa induces infringement of Amarin’s patented cardiovascular indication. The dispute centers on whether generic marketing that references the branded drug’s market size can...
Johnson & Johnson’s Pipeline Strategy: What Does 2026 Have in Store for the Big Pharma?
Johnson & Johnson entered 2026 aiming for $100‑$101 billion in sales after a 9.1 % Q4 revenue rise to $24.6 billion. The company is banking on its oncology portfolio—particularly Darzalex, Tecvayli, Carvykti and emerging lung‑cancer combos—to offset the imminent loss of exclusivity for...
Building a Smart Oncology Pipeline with Cumulus Oncology
Dr. Clare Wareing, founder and CEO of Cumulus Oncology, discussed the company’s risk‑adjusted preclinical pipeline aimed at high‑unmet‑need cancers. Cumulus employs a platform‑agnostic, precision‑medicine strategy that prioritizes patient subgroups to improve development success. The interview highlighted the supportive Scottish biotech...
Seven Italian Biotechs to Know About in 2026
Italy’s biotech sector, though less visible, hosts several companies poised for global impact in 2026. AAVantgarde Bio secured a $141 million Series B to launch dual‑AAV gene therapies for Stargardt disease and Usher syndrome, while Genenta Science rebranded as Saentra Forge to broaden...
How the University of North Carolina at Chapel Hill Is Enhancing RNAi Potency with Its New Technology
The University of North Carolina at Chapel Hill has unveiled a DNA‑based platform that adds deoxythymidine (dT) overhangs to the 5′ end of the antisense strand of siRNAs. This modification dramatically improves guide‑strand loading into the RNA‑induced silencing complex, delivering...
A Clearer Path to Relief: Sinusitis Treatments on the Way
The FDA is poised to approve Dupixent for allergic fungal rhinosinusitis, marking its ninth indication and expanding treatment options for adults and children over five. Phase‑3 data showed a 50% reduction in nasal congestion and a 60.8% shrinkage of nasal...
Top 5 Trends that Will Drive Biopharma in the Next Decade with Tim Opler
Tim Opler, Managing Director at Stifel’s Global Healthcare Group, released his December 2025 Biopharma Market Update outlining five macro‑trends that will shape the industry over the next ten years. He highlights an accelerating M&A wave, the emergence of multi‑trillion‑dollar therapeutic markets...
Hepatitis B: Are We Edging Closer to a Cure?
Hepatitis B infects about 254 million people and caused 1.1 million deaths in 2022, with chronic infection leading to cirrhosis and liver cancer. Researchers are pursuing a “functional cure”—sustained undetectable HBV DNA and loss of HBsAg—through novel antivirals, antisense oligonucleotides, and therapeutic...
From Science to Scale: Building Biotech Companies via Milestone Leadership
Leadership quality now rivals scientific innovation as a key driver of venture‑capital success in biotech. A new "milestone leadership" framework proposes using dynamic scorecards to match executive competencies with each development stage, from pre‑clinical discovery to commercial launch. Companies that...
JPM 2026: What’s the Outlook Like This Year?
The J.P. Morgan Healthcare Summit in San Francisco highlighted a surge in radiopharmaceutical development, positioning precision radiation therapy as a key growth area in oncology. AI‑driven molecular profiling is accelerating biomarker discovery and drug design, while the GLP‑1 market expands with...
Labiotech’s 15 Biopharma Companies to Watch in 2026
Labiotech‑EU hosted a special podcast where journalists Jules Adam, Roohi Peter and Willow Shah‑Neville each highlighted five biotech firms they expect to shape 2026, creating a curated list of 15 companies. The selections span gene‑therapy, immunology, neuroscience and platform technologies, featuring names such...
The AbbVie Strategy, a Company at an Inflection Point
AbbVie’s historic reliance on Humira has been upended by a 54.5% U.S. revenue drop as biosimilars entered in 2023, prompting a strategic pivot toward its next‑generation immunology drugs Skyrizi and Rinvoq. The company projects combined revenue of over $31 billion from...
Seven Biotech Companies to Know in the Netherlands
The Netherlands hosts a dense biotech ecosystem anchored by hubs such as Leiden Bio Science Park, which supports over 400 firms and 25,000 jobs. Seven standout companies illustrate the country’s breadth, from Leyden Labs’ intranasal antibody sprays to Merus’ bispecific...
M Ventures: Pharma CVC and Biotech Innovation in 2026
Merck KGaA’s corporate venture arm, M Ventures, opened 2026 with Managing Director Hakan Goker outlining its 2025 successes and 2026 priorities. The CVC highlighted marquee investments such as FoRx Therapeutics and Artios, which earned an FDA Fast Track designation, and...
Can the Thymus Be Drugged? TECregen Raises $12 Million to Find Out
Swiss biotech TECregen announced a CHF 10 million ($12.5 million) seed round led by Boehringer Ingelheim Venture Fund and appointed Bo Rode Hansen as chairman of its board. The company is developing “thymopoietics,” engineered biologics designed to rejuvenate thymic epithelial cells and restore thymus‑driven naive...
When Biotech Makes Christmas Miracles Happen — Second Edition
The article revisits three recent biotech breakthroughs that felt like miracles: base‑edited CAR‑T cells (BE‑CAR7) delivering remission for relapsed T‑ALL, ex vivo gene‑corrected skin grafts curing severe junctional epidermolysis bullosa, and prenatal enzyme replacement therapy mitigating infantile Pompe disease. Each case...
U.S. Vaccine Approvals to Undergo Overhaul: What Do the Changes Mean?
The U.S. FDA has disclosed a draft overhaul that would tighten vaccine approval standards, requiring developers to submit expanded safety and efficacy data and potentially subject annual flu shots to large‑scale trials. Simultaneously, the CDC withdrew its universal hepatitis B vaccination...
Johnson & Johnson’s Hematology Portfolio: Breakthroughs to Watch
Johnson & Johnson showcased a robust hematology pipeline at the ASH 2025 meeting, unveiling more than 60 new abstracts. The company highlighted real‑world evidence from thousands of patients, underscoring the efficacy of its CAR‑T, bispecific and gene‑editing therapies. Notably, the...
Eight of the Biggest Immunology and Inflammation (I&I) Deals in 2025
In 2025 the immunology and inflammation sector saw eight blockbuster partnerships, each worth between $1.7 billion and $4 billion. Deals ranged from AstraZeneca’s $175 million upfront, $4.4 billion‑potential collaboration with Harbour BioMed to Vor Bio’s surprising $4 billion licensing of telitacicept despite a massive wind‑down....
Biotech in 2025: A Retrospective
2025 marked a phase shift in biotech as metabolic health, AI, and radiopharmaceuticals moved from hype to mainstream impact. GLP‑1 and related incretin drugs expanded into broader cardiometabolic indications, with over 40 candidates in development and major licensing deals reshaping...
Lisbon Is Calling: The BIO-Europe Startup Spotlight Returns in March 2026
BIO‑Europe’s Startup Spotlight, the premier European biopharma pitch competition, announced its 2025 champion, German spin‑out Fusix Biotech, which secured the trophy in Vienna with its InFUSE chimeric oncolytic virus platform. The contest selects eight early‑stage companies—fewer than 25 employees and...
Keep an Eye on These 15 Biotech Companies in 2026
Labiotech’s 2026 "biotechs to watch" list spotlights fifteen companies across gene therapy, cell therapy, base editing, radiopharma and metabolic disease, each with pivotal clinical or regulatory milestones slated for the coming year. Highlights include AAVantgarde’s $141 million Series B and proof‑of‑concept trials...
Fifteen Gift Ideas for a Biotech Enthusiast This Holiday Season
The article curates fifteen holiday gift ideas tailored for biotechnology enthusiasts, ranging from playful items like the Viral board game to advanced tools such as portable DNA sequencers. It highlights novelty products—including glow‑in‑the‑dark mushrooms, DNA‑shaped cookie cutters, and personalized DNA...
Tackling Pulmonary Fibrosis: Boehringer Ingelheim’s New Drug + AI Approach
Boehringer Ingelheim has launched the first new pulmonary‑fibrosis medicine in more than a decade, an oral PDE4B inhibitor that secured FDA approval and will be rolled out globally. The company also introduced eLung, an AI‑driven imaging tool that spots microscopic...